文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

MDMA辅助心理治疗重度PTSD的随机双盲安慰剂对照3期试验

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study.
PubMed 文献 · Nat Med · 2021-05-10

该多中心3期试验将90例重度PTSD患者按1:1随机分配至MDMA辅助治疗组或安慰剂辅助治疗组,联合三次准备性及九次整合性心理治疗。结果显示MDMA显著降低CAPS-5评分(P<0.0001,d=0.91)及SDS总分(P=0.0116,d=0.43),且未诱导滥用潜力、自杀倾向或QT延长等不良事件。

要点

  • MDMA辅助治疗显著减轻重度PTSD症状(CAPS-5改善,效应量d=0.91)。
  • MDMA辅助治疗显著改善功能损害(SDS总分下降,效应量d=0.43)。
  • MDMA未诱导滥用潜力、自杀倾向或QT延长等不良事件。

核心结论

  • 与安慰剂辅助治疗相比,MDMA辅助治疗对重度PTSD高效,且安全耐受,包括共病患者。

研究设计与样本

  • 随机、双盲、安慰剂对照、多中心3期临床试验(NCT03537014),纳入90例重度PTSD患者。

主要发现

  • MDMA组CAPS-5评分变化均值为-24.4(s.d. 11.6),安慰剂组为-13.9(s.d. 11.5)。
  • MDMA较安慰剂显著降低CAPS-5评分(P<0.0001,d=0.91)和SDS总分(P=0.0116,d=0.43)。
  • MDMA未诱导滥用潜力、自杀倾向或QT延长等不良事件。

关键数值与推荐

  • 主要终点为CAPS-5评分,次要终点为SDS评分,于末次实验 session 后2个月评估。

临床怎么用

  • MDMA辅助心理治疗可作为重度PTSD(含常见共病)的潜在突破性治疗选择。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Post-traumatic stress disorder (PTSD) presents a major public health problem for which currently available treatments are modestly effective. We report the findings of a randomized, double-blind, placebo-controlled, multi-site phase 3 clinical trial (NCT03537014) to test the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted therapy for the treatment of patients with severe PTSD, including those with common comorbidities such as dissociation, depression, a history of alcohol and substance use disorders, and childhood trauma. After psychiatric medication washout, participants (n = 90) were randomized 1:1 to receive manualized therapy with MDMA or with placebo, combined with three preparatory and nine integrative therapy sessions. PTSD symptoms, measured with the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5, the primary endpoint), and functional impairment, measured with the Sheehan Disability Scale (SDS, the secondary endpoint) were assessed at baseline and at 2 months after the last experimental session. Adverse events and suicidality were tracked throughout the study. MDMA was found to induce significant and robust attenuation in CAPS-5 score compared with placebo (P < 0.0001, d = 0.91) and to significantly decrease the SDS total score (P = 0.0116, d = 0.43). The mean change in CAPS-5 scores in participants completing treatment was -24.4 (s.d. 11.6) in the MDMA group and -13.9 (s.d. 11.5) in the placebo group. MDMA did not induce adverse events of abuse potential, suicidality or QT prolongation. These data indicate that, compared with manualized therapy with inactive placebo, MDMA-assisted therapy is highly efficacious in individuals with severe PTSD, and treatment is safe and well-tolerated, even in those with comorbidities. We conclude that MDMA-assisted therapy represents a potential breakthrough treatment that merits expedited clinical evaluation.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Mitchell JM, Bogenschutz M, Lilienstein A, et al. MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study. Nat Med. 2021. PMID: 33972795. doi:10.1038/s41591-021-01336-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。